Bullfrog AI Holdings, Inc., a prominent digital biopharmaceutical company operating within the Health Care sector, is poised to make significant strides in the realm of AI-driven drug development. Headquartered in Gaithersburg, United States, Bullfrog AI is dedicated to harnessing artificial intelligence to identify and analyze meaningful data, thereby enhancing the efficiency of drug development processes. This innovative approach not only serves their U.S.-based customer base more effectively but also positions the company as a leader in the integration of AI technology within the healthcare industry.
As of September 7, 2026, Bullfrog AI’s stock is trading at a close price of $0.482 on the Nasdaq exchange. The company’s market capitalization stands at $9,330,000 USD, reflecting its current valuation in the market. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $2.04 on October 7, 2025, and a low of $0.425 on February 11, 2026. Despite these variations, Bullfrog AI continues to focus on its core mission of advancing AI technology in biopharmaceuticals.
A notable aspect of Bullfrog AI’s financial metrics is its price-to-earnings ratio, which is currently at -1.31. This figure indicates that the company is not yet profitable, a common scenario for many innovative tech firms in their growth phases. However, the company’s strategic initiatives and upcoming investor engagements suggest a forward-looking approach aimed at driving future growth and profitability.
In the coming weeks, Bullfrog AI Holdings, Inc. is set to participate in two key investor conferences, underscoring its commitment to transparency and investor relations. On September 15 and 16, the company will be featured at the iAccess Alpha Virtual Best Ideas Fall Investment Conference. CEO Vin Singh is scheduled to deliver a presentation at 2:00 PM ET on the first day, followed by one-on-one meetings with institutional investors on the second day. These engagements provide an opportunity for investors to gain deeper insights into the company’s strategic direction and technological advancements.
Further amplifying its investor outreach, Bullfrog AI will also participate in the Water Tower Research Insights Conference from September 22 to 23. A fireside chat with CEO Vin Singh is planned for 1:00 PM ET on September 23, offering a platform for open dialogue and discussion about the company’s future prospects. All presentations from these conferences will be webcast and subsequently archived on Bullfrog AI’s investor relations website, ensuring accessibility for a broader audience.
At the heart of Bullfrog AI’s platform is its AI-accelerated biomedical data analysis capabilities. The company offers a suite of services, including biology-aware data harmonization, causal analytics, and structured decision support. These tools are designed to be traceable and subject to scientific review, ensuring that the data-driven insights provided are both reliable and actionable. By focusing on these advanced analytical capabilities, Bullfrog AI aims to revolutionize the drug development landscape, making it more efficient and effective.
As Bullfrog AI Holdings, Inc. continues to navigate the dynamic landscape of the healthcare sector, its strategic focus on AI technology and investor engagement positions it well for future growth. With a clear vision and a robust platform, the company is well-equipped to address the challenges and opportunities that lie ahead in the biopharmaceutical industry.
